Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2014-10-31
2017-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Auditory Rehabilitation and Cognition in Alzheimer Patients
NCT03002142
Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia
NCT07288463
Integration of Health Information Technology and Promotion of Personhood in Family-Centered Dementia Care
NCT04571502
OTC Hearing Aid and MCI
NCT06112860
Developing an Artificial Intelligence System to Detect Cognitive Impairment
NCT05794451
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The main research question in this study is: Will persons with AD demonstrate benefit from the use of hearing aids, where benefit is measured through questionnaires assessing activities of daily living, communication, and social functioning. We hypothesize that participants with AD in the intervention group (i.e., those who receive hearing aids) will have a larger improvement in overall functioning at the end of a one-month and three-month period than participants with AD in two control groups. Furthermore, we hypothesize that a group of cognitively normal control participants will demonstrate similar gains in functioning to those participants with AD. Finally, we hypothesize that a similar disparity in benefit between the intervention and control groups will be seen for the participants' caregivers. The specific objectives for this project are to determine, for people with AD if … a) they can benefit from hearing aids based on common audiologic outcome measures, as well as measures of communication function and activities of daily living, and if such benefits depend on variations in current audiologic practice; b) they can benefit from hearing aids with regard to measures of severity of cognitive, behavioural and psychological symptoms of dementia and related caregiver burden; c) hearing aids can bolster their family caregivers' psychological well-being, relationship with, and perceived burden related to caring for and communicating with someone who suffers from both AD and hearing loss, and if specific issues related to communication and audiologic rehabilitation are identified as important by caregivers; and d) the beneficial effects of the hearing aid intervention on the person and their caregiver can be maintained at three months post-fitting.
A randomized control design will be used with three groups of AD patients randomly assigned to 1) intervention (immediate hearing aid fitting), 2) wait-list control (no hearing aid intervention) or 3) active control (no hearing aid intervention + using a new form of fitness technology). A final group of controls with normal cognition will also be tested. All participants will undergo an assessment of their cognition. They and their family caregivers will complete a battery of measures on at least three occasions: once right before the hearing aid fitting is completed to provide a baseline (1), as well as one-month (2) and three-months (3) post-fitting. Participants in the control groups will also complete a set of additional assessments corresponding to the timeline for the hearing aid fitting of participants in the interventions groups (i.e., they will complete 5 assessments rather than 3). In addition to the study sessions, all participants will also complete standard audiology appointments including hearing testing, hearing aid evaluation, hearing aid fitting, and hearing aid checking.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD_HI
This group will consist of participants with Alzheimer's disease who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
Standard audiologic rehabilitation (incl. HI)
The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
NC_HI
This group will consist of participants with normal cognition (i.e., no diagnosis of Alzheimer's disease) who receive treatment (Standard audiologic rehabilitation (incl. HI)) immediately and are followed over a three-month intervention period.
Standard audiologic rehabilitation (incl. HI)
The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard audiologic rehabilitation (incl. HI)
The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pure-tone threshold at 3 kHz in excess of 35 dB HL in the worse ear
* 60 years of age or older
* Able to read and communicate well in English
* Allow the researchers access to their medication list throughout the study to assess any changes in medications
* Willing to use one or more hearing aid(s) on a regular basis
* Has a caregiver who…
* Is a family member
* Is over the age of 18
* Is able to read and communicate well in English.
* Accompanies participant to Baycrest for all necessary appointments
* Provides qualitative and quantitative assessments of the participant's everyday behaviours and functioning
* Is willing to learn and support the participant in using hearing aid(s), provide information on their own well-being and communication function
* If they currently use one or more hearing aid(s), have acquired said aid(s) at least one year prior and are using it/them in a stable fashion.
Exclusion Criteria
* Has a history of untreated psychiatric illness
* Has an uncorrected deficit in visual acuity or an untreated visual medical issue (e.g., glaucoma, macular degeneration, diabetic retinopathy)
* Suffers from a neurological disorder (e.g., multiple sclerosis, epilepsy)
* Has any untreated medical conditions that could jeopardize participation in the study
* Has been taking medication for their cognitive impairment (e.g., cholinesterase inhibitor, NMDA receptor antagonists) for less than one month.
* Has a caregiver who…
* Is not cognitively stable (e.g., has been diagnosed with mild cognitive impairment or dementia)
* Has a terminal medical or untreated psychiatric conditions that could jeopardize their participation in the study.
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Toronto
OTHER
Baycrest Centre for Geriatric Care
OTHER
Phonak AG, Switzerland
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kathleen Pichora-Fuller, Prof.
Role: PRINCIPAL_INVESTIGATOR
University of Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Baycrest Center of Geriatric Care
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHPHST101659-03HIAD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.